drugset / Trial / NCT06493084

Evaluate LAE102 in Healthy and Overweight/Obese Subjects

NCT06493084

Phase 1 Recruiting 160 enrolled Laekna Limited
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of LAE102 injection in healthy and overweight/obese participants, and also evaluate the preliminary pharmacodynamic effect of multiple dose injections in overweight/obese participants.

Timeline

Start
2024-06-25
Primary completion
2026-09-30
Completion
2026-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject LAE102 Unknown Intravenous

Indications

No indication recorded.